小细胞肺癌肿瘤标志物——胃泌素释放肽前体酶联免疫检测方法的研究进展

Enzyme linked immunosorbent assay of pro gastrin releasing peptide as tumor marker for small cell lung carcinoma: research advances and clinical application

介绍一种新的小细胞肺癌的肿瘤标志物。用基因重组的人胃泌素释放肽前体 (pro gas trin releasingpeptide ,ProGRP)制备单克隆抗体和抗血清 ,建立ProGRP的双抗体夹心酶联免疫检测 (ELISA)方法。临床实验研究显示该检测方法对小细胞肺癌诊断的特异性高 ,对早期小细胞肺癌也有较高的阳性率 ,检测的可靠性也很高。各种临床实验结果也证明 ,ProGRP是临床诊断和鉴别诊断小细胞肺癌的良好的肿瘤标志物 ,而且ProGRP比神经元特异烯醇化酶更适宜用于小细胞肺癌的早期诊断。新近有学者发现在需要血液透析的慢性肾功能衰竭患者中有 96%血清ProGRP超过临界值。因此在临床应用ProGRP免疫检测作为小细胞肺癌的诊断和判断疗效和复发时 ,必须检查患者的肾功能以排除慢性肾功能衰竭所出现的血中ProGRP的升高。

A highly specific,sensitive and convenient enzyme linked immunosorbent assay(ELISA),using recombinant human pro gastrin releasing peptide(ProGRP),was newly developed.It was demonstrated that the determination of serum ProGRP was a reliable clinical tumor marker for small cell lung carcinoma(SCLC),even at the relatively early stage of the disease.Moreover,changes in the serum ProGRP showed excellent correlation with the therapeutic responses in SCLC patients, being superior to neuron specific enolase(NSE)for early diagnosis of SCLC. It was found recently that serum ProGRP concentration was also elevated in patients with chronic renal failure on hemodialysis.The evaluation of renal function state of the patients may be mandatory when serum ProGRP level is to be applied as a diagnostic tool for SCLC or as a marker monitoring their clinical courses. [